Zepbound for MASH and fatty liver: what the SYNERGY-NASH data really shows

TLDR. Tirzepatide (the molecule in Zepbound and Mounjaro) produced histologic MASH resolution in 44 to 62 percent of patients across dose arms in the SYNERGY-NASH phase 2 trial published in NEJM in June 2024. The effect size is the largest seen in any MASH trial to date. There is no FDA indication for MASH yet, no payer coverage under a MASH diagnosis, and the path to approval likely runs through resmetirom-style biomarker endpoints rather than a new histology trial. Patients with biopsy-confirmed MASH and obesity can still get Zepbound through the standard obesity PA route.

Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is the inflammatory progression of fatty liver disease. The bigger umbrella term, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), describes the simple fat accumulation that precedes inflammation. Both are driven by the same metabolic biology that drives obesity and type 2 diabetes. GLP-1 medications and their dual-agonist successors hit that biology head-on.

What SYNERGY-NASH tested

SYNERGY-NASH was a phase 2 trial of tirzepatide in 190 patients with biopsy-confirmed MASH (stage F2 or F3 fibrosis), randomized to tirzepatide 5 mg, 10 mg, 15 mg weekly, or placebo for 52 weeks. Results published in NEJM in June 2024 showed:

• MASH resolution without fibrosis worsening: 44 percent on 5 mg, 56 percent on 10 mg, 62 percent on 15 mg, versus 10 percent placebo.
• Fibrosis improvement of one stage or more: 55 percent on 10 mg and 51 percent on 15 mg, versus 30 percent placebo. The fibrosis effect did not reach significance on 5 mg.
• Body weight reduction: 10 to 16 percent across dose arms.
• Liver fat reduction (MRI-PDFF): 47 to 70 percent across dose arms.

Compared to resmetirom (the first FDA-approved MASH drug, approved March 2024), tirzepatide's MASH-resolution numbers are roughly double. Resmetirom achieved MASH resolution in 26 percent (MAESTRO-NASH 80 mg arm). The tirzepatide effect is meaningfully larger, with the caveat that SYNERGY-NASH was phase 2 and smaller than MAESTRO-NASH.

The ESSENCE program and semaglutide

For context on the broader GLP-1 fatty-liver evidence base, the ESSENCE trial of semaglutide 2.4 mg in MASH reported phase 3 results in late 2024. Topline numbers: 63 percent MASH resolution on semaglutide versus 34 percent placebo, with significant fibrosis improvement at 72 weeks. ESSENCE moves semaglutide closer to a MASH label change than tirzepatide, simply because it is the phase 3 trial, not phase 2.

Both molecules now have credible MASH evidence. Tirzepatide's phase 2 effect size is numerically larger, but phase 3 confirmation is required before regulatory action.

Where coverage actually stands in 2026

Neither Zepbound nor Wegovy is FDA-indicated for MASH or MASLD as of mid-2026. The practical implications:

• No MASH-specific PA path. A prior authorization listing MASH as the qualifying diagnosis will be denied. Plans authorize medications under approved indications, not under emerging evidence.
• The obesity PA route still works. A patient with MASH plus BMI 30 (or BMI 27 plus comorbidity) qualifies for Zepbound under the obesity indication. MASH counts as a comorbidity for the BMI 27 threshold. The PA cites obesity, not MASH.
• The OSA route still works. If the patient also has moderate-to-severe OSA, the OSA indication for Zepbound is a clean pathway. Roughly 35 percent of MASH patients also have OSA.
• The diabetes route still works. If the patient has type 2 diabetes, Mounjaro under the T2D indication is straightforward. Many MASH patients have T2D as a comorbid driver.

The pattern: MASH is the clinical target, but the PA paperwork rides on a different indication. This is normal in obesity-related conditions where the comorbid metabolic disease drives the coverage path.

What will likely change the coverage equation

Three near-term events could open MASH-specific coverage:

1. Eli Lilly files a SYNERGY-NASH-based supplemental indication. Most analysts expect a phase 3 trial to be required first. Realistic timeline: 2027 to 2028 for any potential MASH indication on Zepbound.
2. Novo Nordisk files an ESSENCE-based supplemental indication for Wegovy. ESSENCE was phase 3, so the regulatory path is shorter. Realistic timeline: late 2026 to mid 2027 for a possible MASH indication on Wegovy.
3. Payer policy expansion under existing obesity indication. Some commercial plans now expand obesity-medication coverage criteria when MASH is documented, treating it as a high-priority comorbidity. This is plan-by-plan and not consistent across the market.

The honest patient case

For a patient with biopsy-confirmed MASH and BMI 30:

• Expected MASH resolution on Zepbound 15 mg at 52 weeks: roughly 55 to 65 percent.
• Expected fibrosis improvement: roughly 50 percent.
• Expected weight loss: 15 to 20 percent.
• Cost with commercial insurance and obesity PA approved: $25 to $150 per month.
• Cost cash-pay via LillyDirect vials: $349 to $499 per month.
• Resmetirom alternative (FDA-approved for MASH, March 2024): $1,300 per month before savings card, typically $50 to $200 per month with commercial coverage.

For a patient whose primary clinical concern is liver disease and whose BMI is below 27, the coverage math is harder. Resmetirom is the FDA-approved path. Off-label Zepbound through cash-pay is theoretically possible but practically expensive without an insurance route.

Lab and biopsy considerations

Patients starting Zepbound for an obesity indication who also have MASH should establish baseline liver labs (ALT, AST, GGT, bilirubin, INR, platelets) and a baseline FIB-4 or ELF score. The clinical monitoring overlaps with standard obesity monitoring. Repeat liver labs every 12 weeks during titration is a reasonable schedule. MRI-PDFF or FibroScan to track liver-fat fraction and fibrosis is increasingly common in MASH-aware practices.

Patients who already have a hepatology relationship should keep that clinician in the loop on the Zepbound start. Patients without hepatology contact who have biopsy-confirmed MASH should ask for a referral. The drug effect is large enough that hepatology should know and document the response.

Programs equipped for MASH-aware Zepbound prescribing

The programs most likely to handle the MASH overlap well are obesity-medicine and cardiometabolic specialists who order baseline liver workups as part of standard intake. Form Health writes detailed PAs with comorbidity documentation. Knownwell runs primary-care-integrated metabolic care including liver labs. 9amHealth targets cardiometabolic patients and coordinates with specialty care.

How MASH patients are presenting in 2026

The clinical picture of who walks into an obesity-medicine or hepatology clinic in 2026 with MASH:

• Roughly 60 percent have T2D or prediabetes.
• Roughly 75 percent have BMI 30 or higher.
• Roughly 40 percent have established cardiovascular disease or significant risk factors.
• Roughly 35 percent have OSA.
• Roughly 20 percent are taking statins for primary or secondary prevention.

The comorbidity profile means most MASH patients qualify for Zepbound under at least one approved indication: obesity, OSA, or HFpEF if applicable, or for Mounjaro under T2D if that is the primary metabolic concern. The MASH itself is rarely the limiting factor for coverage; it is the documented qualifying condition that drives the PA.

Resmetirom plus tirzepatide: emerging combination

An emerging clinical pattern in hepatology in 2026 is combination resmetirom plus tirzepatide for patients with both significant MASH and obesity. The two mechanisms (THR-beta agonism for resmetirom, dual GLP-1/GIP for tirzepatide) target liver biology differently. Resmetirom directly targets hepatic lipid metabolism. Tirzepatide reduces hepatic fat indirectly via weight loss and insulin sensitivity, plus possible direct liver effects.

No completed RCT has tested the combination. Clinical experience is limited to case series. The cost of combined treatment is substantial: $1,300 per month resmetirom plus $349 to $499 per month tirzepatide vials, before insurance. Most insurance plans approve one of the two, not both, and patients seeking combination usually pay out of pocket for the second medication.

What to watch on labs and imaging

For MASH patients on Zepbound for an obesity indication, a reasonable monitoring schedule:

• Baseline: ALT, AST, GGT, bilirubin, INR, platelets, A1C, fasting lipids, FIB-4 calculation, MRI-PDFF or FibroScan with CAP/E-stiffness.
• Every 12 weeks during titration: ALT, AST, weight, blood pressure.
• At 26 weeks: Repeat FIB-4, consider repeat FibroScan if baseline showed elevated stiffness.
• At 52 weeks: Repeat MRI-PDFF or FibroScan. Hepatology consultation to assess whether biopsy is warranted (rarely needed if non-invasive markers improve significantly).
• Ongoing: Annual non-invasive assessment, integration with broader cardiometabolic risk monitoring.

The biopsy question is increasingly de-emphasized as non-invasive markers (FIB-4, ELF score, MRI-PDFF, FibroScan) have improved. Most MASH patients in 2026 are diagnosed and monitored without repeat biopsy, reserving biopsy for cases with diagnostic uncertainty or trial enrollment.

The MASH-specific drug pipeline beyond Zepbound

Several MASH-targeted molecules are now in late-stage development:

• Resmetirom (Rezdiffra). Already FDA-approved March 2024. THR-beta agonist. Oral daily.
• Pegozafermin. FGF21 analog, late-stage trials reading out 2026-2027.
• Efruxifermin. Another FGF21 analog with phase 2b/3 data.
• Semaglutide. ESSENCE phase 3 topline late 2024, possible MASH supplemental indication 2026-2027.
• Tirzepatide. SYNERGY-NASH phase 2 mid-2024, phase 3 expected to start 2025-2026.

The MASH drug landscape is going from one approved product in 2024 to potentially five or more by 2028. Combination regimens (THR-beta agonist plus GLP-1, FGF21 plus GLP-1) are likely to emerge once individual molecules are established.

Frequently asked questions

Will Zepbound be FDA-approved for MASH soon?

Phase 2 SYNERGY-NASH data published mid-2024. Phase 3 confirmation is standard before a supplemental indication. Realistic timeline for a MASH-specific Zepbound label change is 2027 to 2028, contingent on phase 3 data.

Should I take Zepbound or resmetirom for my MASH?

Resmetirom is FDA-approved for MASH with fibrosis F2 to F3. Zepbound is not. If you have obesity in addition to MASH, Zepbound covers more clinical ground (weight loss, glycemic control, MASH effect) than resmetirom alone. If you have MASH without obesity, resmetirom is the on-label option. Many hepatologists are now considering combination care in patients with both obesity and MASH.

Will my hepatologist prescribe Zepbound?

Most hepatologists do not directly prescribe weight-loss medications. They will coordinate with obesity medicine, primary care, or endocrinology and continue managing the liver disease. Your obesity-medicine clinician writes the prescription. Your hepatologist tracks the liver response.

Can I use compounded tirzepatide for MASH?

The FDA shortage that allowed broad 503A compounded tirzepatide ended in late 2024. Compounded tirzepatide is now available only under narrow medical-necessity carve-outs. The MASH evidence is on FDA-approved branded tirzepatide. Compounded products are off-label for an off-label use, with the added regulatory exposure of being outside the shortage window.

How long until I see liver improvement on Zepbound?

Liver fat (PDFF or FibroScan CAP) drops measurably within 12 to 24 weeks. Histologic MASH resolution typically requires 52 weeks of treatment, mirroring the SYNERGY-NASH and ESSENCE trial designs. Fibrosis improvement is the slowest endpoint, sometimes requiring 72 to 100 weeks.

For the broader fatty-liver condition page, see our MASH and MASLD condition guide. For the related comorbidity combinations, see MASH with T2D and CKD. For PA letter templates targeting obesity with MASH comorbidity, see obesity with comorbidity PA letter. To compare the two molecules head to head, see tirzepatide versus semaglutide. To check Zepbound program rankings, see best for Zepbound.

Citations

• Loomba R, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH). NEJM 2024;391:299-310. nejm.org/doi/full/10.1056/NEJMoa2401943
• Newsome PN, et al. Semaglutide in Patients with Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE phase 3 topline). Novo Nordisk press release Oct 30 2024. novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=909349
• Harrison SA, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH). NEJM 2024;390:497-509. nejm.org/doi/full/10.1056/NEJMoa2309000
• Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023;77:1797-1835. journals.lww.com/hep/fulltext/2023/05000